Cetuximab, Docetaxel and Cisplatin Shows Activity in Head and Neck Cancer

Share this content:
Cetuximab, docetaxel, and cisplatin (TPEx) regimen as first-line treatment for head and neck cancer showed positive activity
Cetuximab, docetaxel, and cisplatin (TPEx) regimen as first-line treatment for head and neck cancer showed positive activity

The standard first-line treatment option for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) is cetuximab, platinum, and fluorouracil.

However, according to the GORTEC study first published online this week in the journal Annals of Oncology, cetuximab, docetaxel, and cisplatin (TPEx) regimen as first-line treatment for HNSCC showed positive activity.

The multicenter, phase 2 study included fifty-four patients with confirmed HNSCC, performance status with less than or equal to 1, and under 71 years of age. All patients were given the TPEx regimen.

The patients were given G-CSF after each chemotherapy cycle for prophylaxis and cetuximab every two weeks after the end of the treatment cycle for maintenance therapy.

Results showed that the primary endpoint, objective response rate, was met with 44.4% (95% CI: 30.9, 58.6). Moreover, the median overall survival was 14 months (95% CI: 11.3, 17.3) and progression-free survival was 6.2 months (95% CI: 5.4, 7.2).

RELATED: Study Supports Use of PET-CT Guided Active Surveillance in Head and Neck Squamous Cell Cancer

The most common grade 3 and 4 adverse events were skin rash (16.6%) and non-febrile neutropenia (20.4%). The fatal adverse events were pulmonary embolism and infection, which lead to three deaths. 

The study demonstrates that TPEx can be used as first-line treatment for HNSCC with promising activity.


  1. Engelen MPKJ, Safar AM, Bartter T, et al. High anabolic potential of essential amino acid mixtures in advanced non-small cell lung cancer. Ann Oncol. 2015. [epub ahead of print]. doi: 10.1093/annonc/mdv271.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs